Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Lung Cancer. 2013 Dec;82(3):436–440. doi: 10.1016/j.lungcan.2013.10.001

Table 1.

Summaries of patient’s characteristics for CALGB 30002, 30206, and 39808

30002
(N = 34)
30206
(N = 57)
39808
(N = 9)
Overall
(N =100)
Fisher’s exact p-
value for balance
among 3 studies
Gender
Male 16 (47%) 34 (60%) 6 (67%) 56 0.4683
Female 18 (53%) 23 (40%) 3 (33%) 44
Age
Median(min, max) 62 (45, 78) 60 (41, 77) 54 (49, 79) 61 (41, 79) 0.8712
<=59 14 (41%) 25 (44%) 5(56%) 44
60–69 14 (41%) 22 (39%) 2(22%) 38
>=70 6 (18%) 10 (18%) 2(22%) 18
Race
White 32 (94%) 55 (96%) 9(100%) 96 0.7468
Black 2 (6%) 2 (4%) 0(0%) 4
Performance
Status
0 15 (44%) 40 (70%) 3(33%) 58 0.0147
1 18 (53%) 17 (30%) 6(67%) 41
2 1 (3%) 0 (0%) 0(0%) 1
Weight loss
<5% 21 (62%) 48 (84%) 8 (89%) 77 0.1758
5% - <10% 7 (21%) 4 (7%) 1(11%) 12
10%- <20% 1 (3%) 3 (5%) 0 (0%) 4
>=20% 2 (6%) 2 (4%) 0 (0%) 4
Missing 3 (9%) 0 (0%) 0(0%) 3
Pleural Effusion
No 33 (97%) 51 (89%) 9(100%) 93 0.3178
Yes 1 (3%) 6 (11%) 0(0%) 7
b Comparisons between included patients and excluded patients who had completed 4, 5 or 6 cycles of treatment
Excluded &
completed 4+
cycles
N=78
Included
N=100
Overall
N =178
Fisher’s exact p-value
for comparison
between included
and excluded
Gender
Male 33(42%) 56(56%) 89 0.0963
Female 45(58%) 44(44%) 89
Age
Median(min, max) 62(38,79) 0.4667
<=59 35(45%) 44(44%) 79
60–69 34(44%) 38(38%) 72
>=70 9(12%) 18(18%) 27
Race
White 70(90%) 96(96%) 166 0.2162
Black 6(8%) 4(4%) 10
Other 2(2%) 0(0%) 2
Performance Status
0 38(49%) 58(58%) 96 0.3997
1 38(49%) 41(41%) 79
2 2(2%) 1(1%) 3
Weight loss
<5% 53(68%) 76(76%) 129 0.1492
5% - <10% 13(17%) 12(12%) 25
10%- <20% 10(13%) 4(4%) 14
>=20% 2(2%) 4(4%) 6
Missing 0(0%) 4(4%) 4
Pleural Effusion
No 76(97%) 93(93%) 169 0.3022
Yes 2(3%) 7(7%) 9